Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NNOX.
← Back to Free Index

NNOX

Analysis as of: 2026-06-14
Nano-X Imaging Ltd.
Nanox sells FDA-cleared digital tomosynthesis imaging systems plus teleradiology, AI imaging software, cloud workflow, and healthcare IT services.
ai cloud healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Commercialization Has Upside, but Runway Sets the Pace
The opportunity is meaningful because a tiny installed base can expand into a broader imaging-service network if channel execution finally converts. The constraint is equally clear: financing and activation still govern whether that flywheel ever forms.

Analysis

Thesis
Nanox is a distressed but credible option on turning low-cost 3D imaging hardware into a recurring imaging utility; if it secures runway and converts channel deals into live sites, revenue can scale non-linearly from service attach and workflow ownership, but the whole case still hinges on financing and activation discipline.
Last Economy Alignment
Nanox benefits from cheaper AI and workflow automation because each live device can pull through reads, software, and IT services, but it is still constrained by capital, approvals, and incumbent OEM distribution.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
7.8x (from 5 most recent analyses)
Reasoning
The upside does not come from shipping boxes alone. It comes from proving that each deployed system becomes a revenue node for reads, AI, cloud, and healthcare IT, which raises recurring mix and makes the business easier to value. I cap the outcome below software leaders because hardware, approvals, and future dilution still matter even in a good execution case.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is a sequence-risk story. Nanox first needs a credible balance-sheet bridge, then faster activation of installed systems, then proof that those systems support attractive recurring revenue and better gross profit. The upside is real because the valuation base is small and the product is cleared, but missing any gate can force dilution before the flywheel forms.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.25
They control a cleared imaging device and can attach reading, AI, and IT services to every live system, so one successful placement can create several revenue streams. The risk is that cash, permits, and bigger incumbents with broader sales coverage stop the flywheel before it gets big.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case